BMBF-Network CHAMP: Childhood allergy and tolerance - biomarkers and predictors
- Speaker: Prof. Dr. Bianca Schaub
- Affiliation: Children's clinic and children's policlinic in Dr. von Hauner'schen Kinderspital
- Funding by BMBF: 2017 to 2021
The CHAMP Consortium aims to investigate the determinants of different allergic diseases (food allergy, atopic dermatitis, asthma, hay fever) across the whole pediatric age range. Particular attention will be given to factors determining primary tolerance (no onset of disease) and acquired tolerance (remission of existing disease). We will identify clinically relevant biomarkers predicting early onset, progression and remission. As main results, we aim to define a molecular allergy score early in life predicting subsequent allergy risk, to identify predictors of natural tolerance of food allergy and to assess underlying mechanisms in murine models of allergy development with focus on early tolerance induction. We aim to predict mild versus severe allergic diseases, to identify relevant biomarkers and to predict remission of asthma and hay fever. Finally, we expect to HRQoL of patients and quality of life (QoL) of their parents across different allergic diseases, different disease stages and various age groups.
Importantly, this consortium has the unique opportunity to assess the development and remission of childhood allergies at all stages of childhood immune and organ development. In summary, adding novel insight to the puzzle of early onset, natural tolerance and remission of different allergic diseases from birth to adolescence will lay the ground for future development of preventive strategies and shall in the long term contribute to opening up novel avenues for therapeutic options. This will clearly make an impact on the life of our patients and their families.
Source: CHAMP